Lanreotide 60 mg, 90 mg, 120 mg Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 60 mg, 90 mg, 120 mg

Reference Brands: omatuline Depot (USA), Somatuline Autogel (USA)

Category: Oncology Cancer Care

Lanreotide is a synthetic octapeptide analogue of somatostatin. It binds to somatostatin receptors (SSTR‑2 and SSTR‑5), inhibiting secretion of growth hormone and other hormones. It is used to treat Acromegaly when surgery/radiotherapy are not suitable and to manage certain neuroendocrine tumours, including gastrointestinal/pancreatic NETs and symptoms of Carcinoid syndrome.

Product Description:

Lanreotide acetate is a long-acting somatostatin analogue used in the management of hormonal disorders and certain neuroendocrine tumors. It is primarily indicated for the treatment of acromegaly caused by growth hormone–secreting tumors of the pituitary or non-pituitary origin. By mimicking the natural hormone somatostatin, lanreotide helps reduce the secretion of growth hormone and insulin-like growth factor-1 (IGF-1), thereby controlling disease symptoms and biochemical markers. It is also used to manage symptoms associated with neuroendocrine tumors, particularly carcinoid tumors and VIPomas, where it helps control hormone-related effects such as flushing and diarrhea. In some regions such as the United Kingdom, it is additionally indicated for thyrotrophic adenoma (TSH-secreting pituitary tumors). Lanreotide is administered as a prolonged-release deep subcutaneous injection, allowing sustained therapeutic levels with extended dosing intervals. The product is widely marketed under the brand name Somatuline and is manufactured by Ipsen. It is approved and available in multiple international markets including the United States, United Kingdom, Canada, and Australia for specialized endocrine and oncology use.